ACS Chemical Neuroscience · 2014 · 31 citations · 24 references
Life SciencesNeurosciencePharmacologyMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseAmyloid FormationEnzyme InhibitionNeurodegenerative DiseasesNeurodegenerative DisordersProtein AggregationAlzheimer Disease DementiaAlzheimer Disease Tau PathologyAmyloid Beta AggregationAmyloid Beta PeptidesDual-target InhibitorsTau HyperphosphorylationTau-targeted TherapyTherapeutic Targeting Of Amyloid
In Alzheimer's disease (AD), multiple factors account for the accumulation of neurocellular changes, which may begin several years before symptoms appear. The most important pathogenic brain changes that are contributing to the development of AD are the formation of the cytotoxic β-amyloid aggregates and of the neurofibrillary tangles, which originate from amyloid-β peptides and hyperphosphorylated tau protein, respectively. New therapeutic agents that target both major pathogenic mechanisms may be particularly efficient. In this study, we introduce bis(hydroxyphenyl)-substituted thiophenes as a novel class of selective, dual inhibitors of the tau kinase Dyrk1A and of the amyloid-β aggregation.
24
The selectivity of protein kinase inhibitors: a further update
Jenny Bain, Lorna Plater, Matt Elliott et al. · Biochemical Journal · 2007 · 2.5K citations · Full text
Alex E. Roher, Jonathan D. Lowenson, Steven Clarke et al. · Proceedings of the National Academy of Sciences · 1993 · 742 citations
Cynthia A. Lemere, J. K. Blusztajn, H Yamaguchi et al. · Neurobiology of Disease · 1996 · 593 citations · Full text
Ryo Kimura, Kouzin Kamino, Mitsuko L. Yamamoto et al. · Human Molecular Genetics · 2006 · 268 citations · Full text